CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

“CRISPR-by-de­sign” is the idea be­hind Scribe Ther­a­peu­tics, a com­pa­ny spun out from Jen­nifer Doud­na’s No­bel-win­ning lab that’s com­pet­ing in a close­ly-tracked field of genome ed­i­tor com­pa­nies just start­ing to make their way to the clin­ic.

Af­ter nab­bing $100 mil­lion last March for its Se­ries B fund­ing round, Scribe is tak­ing a dif­fer­ent tack from some of its com­peti­tors, craft­ing a new en­zyme iso­lat­ed from bac­te­ria called CasX, which has now been tweaked ex­ten­sive­ly and may be tar­get­ed to a range of genome-re­lat­ed dis­eases, of­fer­ing a pletho­ra of ther­a­peu­tic op­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER